{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:52:44Z","timestamp":1787737964855,"version":"build-2784847793"},"reference-count":67,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012175","name":"Zhejiang Administration Bureau of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["2024ZL011"],"award-info":[{"award-number":["2024ZL011"]}],"id":[{"id":"10.13039\/501100012175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clinthera.2025.04.016","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T15:39:52Z","timestamp":1748014792000},"page":"673-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Peripheral Neuropathy in Patients With Ovarian Cancer Administrating Poly ADP-Ribose Polymerase Inhibitors: A Real-World Study Based on Bayesian Disproportionality Analysis of the US Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1016","volume":"47","author":[{"given":"Chenguang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.04.016_bib0001","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0002","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0003","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription-replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0005","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/ijc.34002","article-title":"Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020","volume":"151","author":"Cabasag","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0006","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2021.08.029","article-title":"Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: cervical, ovarian and uterine cancer","volume":"163","author":"Wang","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0007","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13048-023-01233-y","article-title":"Trends in incidence and mortality for ovarian cancer in China from 1990 to 2019 and its forecasted levels in 30 years","volume":"16","author":"Feng","year":"2023","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0008","unstructured":"Yaorongyun. Market and research analysis report on poly (ADP-ribose) polymerase (PARP) target. https:\/\/www.pharnexcloud.com\/. Accessed November 30, 2024."},{"key":"10.1016\/j.clinthera.2025.04.016_bib0009","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1021\/jm5018237","article-title":"Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination","volume":"58","author":"Jones","year":"2015","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.clinthera.2025.04.016_bib0010","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.chembiol.2024.01.007","article-title":"Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite","volume":"31","author":"Hu","year":"2024","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0011","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3892\/or.2021.8231","article-title":"Metabolism-related pharmacokinetic drug-drug interactions with poly (ADPribose) polymerase inhibitors (Review)","volume":"47","author":"Zhao","year":"2021","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0012","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","article-title":"Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology","volume":"61","author":"Bruin","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0013","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bcp.15015","article-title":"Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale","volume":"88","author":"Sandhu","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0014","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1049909118786958","article-title":"Can poly (ADP-ribose) polymerase inhibitors palliate paclitaxel-induced peripheral neuropathy in patients with cancer?","volume":"36","author":"Balko","year":"2018","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0015","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1089\/jpm.2018.0572","article-title":"ADP-ribose) polymerase inhibition for chemotherapy-induced peripheral neuropathy: a meta-analysis of placebo-controlled trials","volume":"22","author":"Balko","year":"2019","journal-title":"J Palliat Med"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70012","article-title":"DNA damage induced PARP-1 overactivation confers paclitaxel-induced neuropathic pain by regulating mitochondrial oxidative metabolism","volume":"30","author":"Ge","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0017","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41586-023-06727-9","article-title":"Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2","volume":"623","author":"Pidathala","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0018","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2147\/TCRM.S161148","article-title":"Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010-2015","volume":"14","author":"Alshammari","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0019","first-page":"4223","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin","volume":"29","author":"Maih\u00f6fner","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0020","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.mayocp.2015.05.004","article-title":"Peripheral neuropathy: a practical approach to diagnosis and symptom management","volume":"90","author":"Watson","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0021","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1503\/cmaj.220936","article-title":"Diagnosis and management of patients with polyneuropathy","volume":"195","author":"Mirian","year":"2023","journal-title":"CMAJ"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100315","article-title":"Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"6","author":"Omar","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0024","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Noren","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0026","article-title":"PARP inhibitor-related haemorrhages: what does the real-world study say?","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23726-4","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib","volume":"12","author":"Guo","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0028","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.3390\/curroncol30070479","article-title":"Peripheral neuropathy potentially associated to poly (ADP-ribose) polymerase inhibitors: an analysis of the eudravigilance database","volume":"30","author":"Jesus","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0029","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bcp.15015","article-title":"Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale","volume":"88","author":"Sandhu","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0030","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/jjco\/hyab013","article-title":"The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study","volume":"51","author":"Yonemori","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0031","unstructured":"GSK. Full prescribing information for Zejula (niraparib). https:\/\/www.zejula.com\/prescribing-information. Accessed November 30, 2024."},{"key":"10.1016\/j.clinthera.2025.04.016_bib0032","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.3390\/ijms22157931","article-title":"The mechanism of secretion and metabolism of gut-derived 5-hydroxytryptamine","volume":"22","author":"Liu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0033","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s10571-021-01064-9","article-title":"The roles of serotonin in neuropsychiatric disorders","volume":"42","author":"Pourhamzeh","year":"2022","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0034","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.3390\/ijms20092288","article-title":"The serotonin syndrome: from molecular mechanisms to clinical practice","volume":"20","author":"Francescangeli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/CIRCEP.107.750471","article-title":"Altered sympathetic nervous reactivity and norepinephrine transporter expression in patients with postural tachycardia syndrome","volume":"1","author":"Lambert","year":"2008","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0036","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/jnc.15145","article-title":"SLC6 transporter oligomerization","volume":"157","author":"Jayaraman","year":"2021","journal-title":"J Neurochem"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0037","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.tips.2013.07.005","article-title":"Mechanisms of dopamine transporter regulation in normal and disease states","volume":"34","author":"Vaughan","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0038","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ygyno.2024.01.021","article-title":"Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: results from the phase 3 randomized PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"184","author":"Pothuri","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0039","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2018.01.011","article-title":"The poly (ADP ribose) polymerase inhibitor niraparib: management of toxicities","volume":"149","author":"Moore","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0040","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s11910-022-01240-4","article-title":"Updates on the diagnosis and treatment of peripheral autonomic neuropathies","volume":"22","author":"Lamotte","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0041","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: an approach to diagnosis and treatment","volume":"85","author":"Pelosof","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0042","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200316","article-title":"Comprehensive analysis of paraneoplastic neurologic syndrome and PNS-CARE diagnostic criteria in clinical practice","volume":"11","author":"Zhao-Fleming","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0043","doi-asserted-by":"crossref","first-page":"417","DOI":"10.6004\/jnccn.2015.0057","article-title":"Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes","volume":"13","author":"de la","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0044","first-page":"1296","article-title":"Challenges in the identification of cobalamin-deficiency polyneuropathy","volume":"60","author":"Saperstein David","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0045","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1634\/theoncologist.2018-0418","article-title":"Concomitant medications and risk of chemotherapy-induced peripheral neuropathy","volume":"24","author":"S\u00e1nchez-Barroso","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0046","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00228-024-03727-0","article-title":"Neuronal toxicity of monoclonal antibodies (mAbs): an analysis of post-marketing reports from FDA Adverse Event Reporting System (FAERS) safety database","volume":"80","author":"Kumar","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1134436","article-title":"Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years","volume":"14","author":"Ruggiero","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112671","article-title":"Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: an update","volume":"147","author":"Desforges","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0049","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/B978-0-444-64032-1.00027-8","article-title":"Basics of autonomic nervous system function","volume":"160","author":"Gibbons","year":"2019","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ncl.2022.08.002","article-title":"Dysautonomia: diagnosis and management","volume":"41","author":"Hovaguimian","year":"2023","journal-title":"Neurol Clin"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0051","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.clinph.2020.11.024","article-title":"Electrodiagnostic assessment of the autonomic nervous system: a consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology","volume":"132","author":"Cheshire","year":"2021","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0052","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/ana.410140513","article-title":"Quantitative sudomotor axon reflex test in normal and neuropathic subjects","volume":"14","author":"Low","year":"1983","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0053","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1161\/HYPERTENSIONAHA.121.17805","article-title":"Standardized autonomic testing in patients with probable radiation-induced afferent baroreflex failure","volume":"79","author":"Lamotte","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0054","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ygyno.2024.01.012","article-title":"Hypertension associated with niraparib in cancer patients: a pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials","volume":"182","author":"Chen","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0055","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1253\/circj.CJ-88-0020","article-title":"Guidelines for the clinical use of 24 hour ambulatory blood pressure monitoring (ABPM) (JCS 2010): digest version","volume":"76","author":"Shimada","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0056","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/mus.25082","article-title":"Small fiber neuropathy: getting bigger!","volume":"53","author":"Chan","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0057","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/14737175.2020.1794825","article-title":"Clinical diagnosis and management of small fiber neuropathy: an update on best practice","volume":"20","author":"Devigili","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0058","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/jns.12266","article-title":"Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients","volume":"23","author":"Alessandro","year":"2018","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0059","doi-asserted-by":"crossref","first-page":"743","DOI":"10.4093\/dmj.2023.0018","article-title":"Pharmacological and nonpharmacological treatments for painful diabetic peripheral neuropathy","volume":"47","author":"Jang","year":"2023","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0060","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0061","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0062","first-page":"1191","article-title":"Comparative efficacy and safety of PARP inhibitors for advanced ovarian cancer: a systematic review and network meta-analysis","volume":"7","author":"Wu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0063","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. Version 1.2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed August 1, 2020."},{"key":"10.1016\/j.clinthera.2025.04.016_bib0064","unstructured":"Clovis Oncology, Inc. RUCAPARIB tablets, for oral use [prescribing information]. Revised December 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209115s004lbl.pdf. Accessed January 15, 2021."},{"key":"10.1016\/j.clinthera.2025.04.016_bib0065","article-title":"Pharmacovigilance analysis of olaparib using the FDA adverse event reporting system (FAERS)","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0066","first-page":"e114","article-title":"PARP inhibitors in ovarian cancer: a comprehensive review","volume":"24","author":"O\u2019Malley","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2025.04.016_bib0067","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JOP.2014.001776","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary","volume":"10","author":"Hershman","year":"2014","journal-title":"J Oncol Pract"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:02:49Z","timestamp":1763787769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825001602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0149291825001602"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.04.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral Neuropathy in Patients With Ovarian Cancer Administrating Poly ADP-Ribose Polymerase Inhibitors: A Real-World Study Based on Bayesian Disproportionality Analysis of the US Food and Drug Administration Adverse Event Reporting System","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}